3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
Cyclophosphamide
14
Temozolomide
10
Magnetic Resonance Spectroscopy
10
dinutuximab
9
Biopsy
9
X-Rays
8
Specimen Handling
8
Irinotecan
8
Phantoms, Imaging
7
fludarabine
6
Topotecan
6
Nuclear Medicine Department, Hospital
6
Vincristine
5
3-Iodobenzylguanidine
5
sargramostim
4
fludarabine phosphate
4
Melphalan
4
Isotretinoin
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Etoposide
4
tipifarnib
3
Radiotherapy
3
Filgrastim
3
Doxorubicin
3
Colony-Stimulating Factors
3
Carboplatin
3
ulixertinib
2
tazemetostat
2
selpercatinib
2
saponin QA-21V1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.